polymerase chain reaction (PCR), and next generation sequencing (NGS)) often have to be administered, requiring special expertise.
Typing and grading of STB tumors is mandatory for treatment decisions. In this clinical context, in our and most other sarcoma teams, cytology is only applied in selected cases. Firstly, in cases with an established diagnosis of the primary STB tumor, cytology can be effectively used to diagnose recurrent or metastatic sarcoma. Secondly, for deep-located STB tumors, cell material can be collected by fine-needle aspiration (FNAC) during endoscopic ultrasonography (EUS-FNA) or by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS). In our sarcoma team there is ample experience with these techniques. 2, 4, 8 Compared with histological biopsies, it is more easy to sample different tumor areas with fine-needle aspiration (FNA), and this may result in increased diagnostic accuracy, in particular when dealing with
STBs with heterogeneous features on clinical imaging (CT and MRI).
Several different cell block methods can be used to process cell material thus collected. 9 As an adjunct to routinely prepared smears or cell sediments, cytoblock techniques allow the application of IHC and molecular methods, expanding the diagnostic armamentarium. For this purpose, we and others 8, [10] [11] [12] [13] [14] have used the Cellient TM automated cell block system, by which cytotechnicians can make an automated cell block within 1 hour, albeit with higher costs than that of traditional cell block techniques. As described previously, with the Cellient TM method, using methanol fixation instead of formalin, a broad array of diagnostically important antibodies can be applied to IHC after optimization of IHC protocols. In clinical cytology, the Cellient TM method has been used successfully for the characterization of tumor cells in serous fluids and FNAC material, for example, to characterize different carcinoma types or to diagnose metastatic melanoma.
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In this article, we report our first experience on the suitability of the Cellient TM method to diagnose several types of STB tumors, 8 primary lesions (5 of which were gastrointestinal stromal tumors) and 12 secondary recurrences or metastases, applying 9 diagnostically relevant antibodies that were not described in our earlier article of the Cellient TM method.
| M A TER I A L A N D M ETH OD S

| Ethics statement
The study met the criteria of the code of conduct for responsible use of human tissue that is used in the Netherlands (Dutch federation of biomedical scientific societies; http://www.federa.org). 
| Immunohistochemistry
The 14 antibodies (13 monoclonal, 1 polyclonal) applied in this study, including their commercial source, clone, and working dilution, as summarized in Table 2 . Five diagnostically relevant antibodies had been evaluated in our earlier study of the Cellient TM method (CD117, AE1/3, ER, HMB-45, S-100). The 9 additional antibodies used to diagnose the STB tumors in this cohort were actin, beta-catenin, brachyury, caldesmon, CD-34, desmin, DOG-1, myf4, and SATB2. All IHC stains were performed in the Benchmark Ultra automated immunostainer (Ventana, Tuscon, Arizona) using the Ultraview detection system and validated by testing proper dilution of the antibody, need for CC1 antigen retrieval, and need for an 8 minutes amplification step in the IHC staining protocol, respectively (Table 2) . All antibodies had been tested with at least 3 different with protease pretreatment proved to give to best results for cytokeratin antibody AE1-3. For all IHC staining, the Ventana Ultraview DAB detection kit was used with an amplification step of 8 minutes.
Hematoxylin was used as a counterstain. Figure   3A ) and DOG-1 ( Figure 3B ) in GIST, desmin ( Figure 3C ) and HMB-45
( Figure 3D ) in PEComa, SMA ( Figure 3E ) and caldesmon ( Figure 3F ) in leiomyosarcoma, SATB2 in osteosarcoma ( Figure 3G ), S-100 in chondrosarcoma ( Figure 3H ), brachyury in chordoma ( Figure 3I ), myf4 in alveolar rhabdomyosarcoma ( Figure 3J ), ER ( Figure 3K ) in metastatic gynecologic leiomyosarcoma, and CD34 ( Figure 3L ) in dermatofibrosarcoma protuberans.
| D I SCUSSION
The Cellient TM is a fully automated device that produces a cell block within 1 hour based on a standardized protocol. This allows rapid diagnosis on the same day the specimen arrives in the lab instead of the following day, which is convenient in selected cases. A methanol-based PreservCyt TM solution is used instead of formalin. Several research groups have mentioned that the cellularity of Cellient TM material is at least comparable to that in traditional cell blocks, whereas cytomorphological details, in particular chromatin structure, appear to be better. 10, 12, 14 Advantages and disadvantages of commonly used cell block methods including Cellient TM have been amply reviewed by Jain et al. 9 and are summarized in Table 3 . We have noted that the Cellient TM cell blocks often contain small tissue fragments. In addition to H&E interpretation of histological features, IHC and molecular methods, for example, FISH or NGS, can be applied. 8 In the cytology laboratory, immunostaining can be applied to cell smears, ThinPrep specimens, cytospin specimens, and cell blocks. In a UK NEQUAS quality control study, testing commonly used antibodies for a diagnosis of carcinoma, mesothelioma, melanoma, and lymphoma, it was found that the highest sensitivity was provided by cell blocks, followed by cytospin specimens, liquid-based cytology slides, and cell smears. 15 Although cellular DNA and RNA are well preserved by methanol fixation, at the protein level, IHC protocols that are routinely used for FFPE material, have to be optimized and validated. We 8 and Sauter et al. 13 have extensively tested many different antibodies for Cellient TM material using the automated Ventana Benchmark immunostainer. In our initial study published in 2013, we showed that IHC performed on Cellient TM cell blocks could be applied to diagnostic algorithms that proved to be helpful in the discrimination of major tumor types (carcinoma, lymphoma, melanoma, and germ cell tumors), discrimination of carcinoma subtypes (adenocarcinoma, squamous-cell carcinoma, and neuroendocrine carcinoma), and determination of primary tumor site (eg, lung and breast) in cases of metastatic carcinoma. Notably, in a consecutive series of 100 cases, additional and clinically relevant information was obtained in 25% of serous fluid specimens and 29% of FNA specimens.
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